Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects (2014)
- Authors:
- USP affiliated authors: HIRATA, MARIO HIROYUKI - FCF ; RODRIGUES, ALICE CRISTINA - ICB ; DOREA, EGIDIO LIMA - HU ; HIRATA, ROSARIO DOMINGUEZ CRESPO - FCF
- Unidades: FCF; ICB; HU
- DOI: 10.1016/j.jacl.2014.02.008
- Subjects: POLIMORFISMO; COLESTEROL; FARMACOLOGIA; LIPÍDEOS; NUCLEOTÍDEOS; FARMACOGENÉTICA; LIPOPROTEÍNAS LDL; REAÇÃO EM CADEIA POR POLIMERASE; PLASMA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Journal of Clinical Lipidology
- ISSN: 1933-2874
- Volume/Número/Paginação/Ano: v. 8, n. 3, p. 256-264, 2014
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
ANDERSON, Jacqueline M. et al. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects. Journal of Clinical Lipidology, v. 8, n. 3, p. 256-264, 2014Tradução . . Disponível em: https://doi.org/10.1016/j.jacl.2014.02.008. Acesso em: 16 abr. 2024. -
APA
Anderson, J. M., Cerda, A., Hirata, M. H., Rodrigues, A. C., Dórea, E. L., Bernik, M. M. S., et al. (2014). Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects. Journal of Clinical Lipidology, 8( 3), 256-264. doi:10.1016/j.jacl.2014.02.008 -
NLM
Anderson JM, Cerda A, Hirata MH, Rodrigues AC, Dórea EL, Bernik MMS, Bertolami MC, Faludi AA, Hirata RDC. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects [Internet]. Journal of Clinical Lipidology. 2014 ; 8( 3): 256-264.[citado 2024 abr. 16 ] Available from: https://doi.org/10.1016/j.jacl.2014.02.008 -
Vancouver
Anderson JM, Cerda A, Hirata MH, Rodrigues AC, Dórea EL, Bernik MMS, Bertolami MC, Faludi AA, Hirata RDC. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects [Internet]. Journal of Clinical Lipidology. 2014 ; 8( 3): 256-264.[citado 2024 abr. 16 ] Available from: https://doi.org/10.1016/j.jacl.2014.02.008 - Relationships among CYP3A4 and CYP3A5 haplotypes, mRNA expression, CYP3A activity and atorvastatin response in hypercholesterolemic individuals
- Differentiation of african components of ancestry to stratify groups in a case-control study of a brazilian urban population
- Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response
- Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients
- Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin
- Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression
- The contribution of genetic polymorphisms in 60 candidate genes to variability in atorvastatin response
- CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia
- Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients
- Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response
Informações sobre o DOI: 10.1016/j.jacl.2014.02.008 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
